Pfizer, Teva reach deal to allow launch of generic Viagra by 2017
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
Pfizer says Teva will pay an undisclosed royalty for a license to produce a generic version of Viagra, one of New York-based Pfizer's bestselling drugs. Viagra generated about $1.14 billion in U.S. sales last year.
Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.
Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.
The patent protecting another erectile dysfunction drug, Eli Lilly and Co.'s Cialis, also expires in 2017.
Read more Business News
- Evacuation orderBC - 12:43 pm
- Workers recalled at SRICentral Okanagan - 11:09 am
- Wet wood, big smokeKelowna - 1:58 pm
- Killed in Stanley ParkBC - 11:50 am
|QHR Technologies Inc||1.35||+0.13|
|Anavex Life Sciences||0.36||-0.02|
|Copper Mountain Mining||2.49||+0.16|
|Sunrise Resources Ltd||0.03||+0.005|
|Mission Ready Services||0.25||0.00|
Our ability to live beyond our years has nothing to do with medical science; we will all live longer than our physical bodies, each of us will leave behind a personal legacy made up of our deeds, our ...
With all of the adventure activities I have done and still do, I wonder sometimes if the edge still exists. The systematic approach to learning a new adventure or extreme activity combined with the r...
How much time should you put into prospecting? The question is a bit of a puzzle. Ideally, there would be a reference book that lists, by industry, how much time you should invest in prospecting acti...